(Reuters) – Synthetic Biologics Inc said on Thursday its experimental product designed to reduce antibiotic-resistant infections outperformed a placebo in a mid-stage trial. The company’s oral enzyme ribaxamase met the main goal of significantly reducing Clostridium difficile infection (CDI) versus a placebo in the 412-patient study. Prolonged use of antibiotics can allow this common intestinal inhabitant to explode into a lethal infection as antibiotics kill off its beneficial rivals in the gut. Spread through hospital surfaces and human contact, C. difficile most often affects the elderly. …
View post:
Synthetic Biologics’ C. difficile mid-stage study meets main goal